156 related articles for article (PubMed ID: 23510598)
21. [Therapeutic strategies using VEGF inhibitors in colorectal cancer].
Boige V; Malka D; Ducreux M
Bull Cancer; 2005 Aug; 92(Spec no):S29-36. PubMed ID: 16387667
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
Goldberg RM; Hurwitz HI; Fuchs CS
Clin Adv Hematol Oncol; 2005 Dec; 3(12):1-10; quiz 11. PubMed ID: 16555433
[TBL] [Abstract][Full Text] [Related]
23. New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.
Taylor M; Rössler J; Geoerger B; Vassal G; Farace F
Expert Opin Investig Drugs; 2010 Jul; 19(7):859-74. PubMed ID: 20470190
[TBL] [Abstract][Full Text] [Related]
24. Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.
Loupakis F; Bocci G; Pasqualetti G; Fornaro L; Salvatore L; Cremolini C; Masi G; Danesi R; Del Tacca M; Falcone A
Curr Cancer Drug Targets; 2010 Feb; 10(1):37-45. PubMed ID: 20088795
[TBL] [Abstract][Full Text] [Related]
25. Molecular predictors of response to chemotherapy in colorectal cancer.
Dienstmann R; Vilar E; Tabernero J
Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
[TBL] [Abstract][Full Text] [Related]
26. Integration of anti-vascular endothelial growth factor therapies with cytotoxic chemotherapy in the treatment of colorectal cancer.
Oliveira SC; Machado KK; Sabbaga J; Hoff PM
Cancer J; 2010; 16(3):220-5. PubMed ID: 20526100
[TBL] [Abstract][Full Text] [Related]
27. Targeted treatments in colorectal cancer: state of the art and future perspectives.
Arnold D; Seufferlein T
Gut; 2010 Jun; 59(6):838-58. PubMed ID: 20551469
[TBL] [Abstract][Full Text] [Related]
28. [Are antiangiogenic antibodies universal for solid tumor?].
Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
[TBL] [Abstract][Full Text] [Related]
29. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Collins TS; Hurwitz HI
Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
[TBL] [Abstract][Full Text] [Related]
30. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
Bodoky G
Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer.
Ellis LM
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S1-7. PubMed ID: 17145519
[TBL] [Abstract][Full Text] [Related]
32. The present and future of angiogenesis-directed treatments of colorectal cancer.
O'Dwyer PJ
Oncologist; 2006 Oct; 11(9):992-8. PubMed ID: 17030640
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
35. Anti-VEGF therapy: the search for clinical biomarkers.
Longo R; Gasparini G
Expert Rev Mol Diagn; 2008 May; 8(3):301-14. PubMed ID: 18598109
[TBL] [Abstract][Full Text] [Related]
36. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?
Mancuso A; Sternberg CN
Crit Rev Oncol Hematol; 2005 Jul; 55(1):67-81. PubMed ID: 15890525
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
Zondor SD; Medina PJ
Ann Pharmacother; 2004; 38(7-8):1258-64. PubMed ID: 15187215
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
39. Molecular markers in the treatment of metastatic colorectal cancer.
Wilson PM; Labonte MJ; Lenz HJ
Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
[TBL] [Abstract][Full Text] [Related]
40. Molecular mechanisms and targeting of colorectal cancer.
Vanhoefer U
Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]